Trial Profile
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2025
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms QUILT-3.088
- Sponsors ImmunityBio
Most Recent Events
- 21 Jan 2023 Updated results (n=83) assessing updated results of the fully enrolled cohort of a novel combination immunotherapy protocol of low-dose chemoradiation, cytokine-induced NK and T cell activation via N-803 (an IL-15 cytokine superagonist ), and allogeneic off-the-shelf PDL1-targeted high-affinity NK cell (PDL1 t-haNK) infusion presented at the 2023 Gastrointestinal Cancers Symposium
- 23 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Aug 2018 Planned initiation date changed from 29 Jun 2018 to 1 Aug 2018.